Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus. (November 2010)

• Record Type: Journal Article
• Authors: Swen, Jesse J; Wessels, Judith AM; Krabben, Annemarie; Assendelft, Willem JJ; Guchelaar, Henk-Jan
• Is Part Of: Pharmacogenomics. Volume 11:Number 11(2010)
• Page Start: 1517
• Page End: 1523
• Publication Date: 2010-11
• Subjects: CYP2C9 -- glibenclamide -- gliclazide -- glimepiride -- pharmacogenetics -- sulfonylureas -- tolbutamide -- Type 2 diabetes mellitus; Pharmacogenomics -- Periodicals; 615.1
• DOI: 10.2217/pgs.10.121
• Languages: English
• ISSNs: 1462-2416

Abstract

Aims: Sulfonylureas are mainly metabolized by the enzyme CYP2C9. Two allelic variants, CYP2C9*2 and CYP2C9*3, result in decreased metabolic capacity and have been associated with elevated sulfonylurea serum levels. However, most of the available data originates from pharmacokinetic analyses performed in healthy individuals. In this study, the effect of CYP2C9*2 and CYP2C9*3 alleles on prescribed dose and time-to-stable dose of sulfonylureas was investigated.Materials & methods: A group of 207 incident sulfonylurea users treated in four university affiliated primary care centers were identified. The effect of the CYP2C9*2 and CYP2C9*3 alleles on prescribed dose and time-to-stable dose was then assessed.Results: No significant effects of the CYP2C9*2 and CYP2C9*3 alleles were found. However, a trend towards a lower stable glimepiride dose for carriers of the CYP2C9*3 allele was observed.Conclusion: Genotyping for the CYP2C9*2 and CYP2C9*3 alleles currently appears to have no clinical implications for dosing of sulfonylureas in primary care patients with Type 2 diabetes mellitus.